Amanda E. I. Proudfoot
Serono Pharmaceutical Research Institute
14 Chemin des Aulx
1228 Plan-les-Ouates
Geneva
Switzerland
Name/email consistency: high
- The biological relevance of chemokine-proteoglycan interactions. Proudfoot, A.E. Biochem. Soc. Trans. (2006)
- Strategies for chemokine antagonists as therapeutics. Proudfoot, A.E., Power, C.A., Rommel, C., Wells, T.N. Semin. Immunol. (2003)
- Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proudfoot, A.E., Handel, T.M., Johnson, Z., Lau, E.K., LiWang, P., Clark-Lewis, I., Borlat, F., Wells, T.N., Kosco-Vilbois, M.H. Proc. Natl. Acad. Sci. U.S.A. (2003)
- Chemokine receptors: multifaceted therapeutic targets. Proudfoot, A.E. Nat. Rev. Immunol. (2002)
- The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. Proudfoot, A.E., Fritchley, S., Borlat, F., Shaw, J.P., Vilbois, F., Zwahlen, C., Trkola, A., Marchant, D., Clapham, P.R., Wells, T.N. J. Biol. Chem. (2001)
- The strategy of blocking the chemokine system to combat disease. Proudfoot, A.E., Power, C.A., Wells, T.N. Immunol. Rev. (2000)
- Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. Proudfoot, A.E., Buser, R., Borlat, F., Alouani, S., Soler, D., Offord, R.E., Schröder, J.M., Power, C.A., Wells, T.N. J. Biol. Chem. (1999)
- Chemokine receptors--future therapeutic targets for HIV?. Proudfoot, A.E., Wells, T.N., Clapham, P.R. Biochem. Pharmacol. (1999)